drugset / Trial / NCT00072410
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Phase 1
Completed
7 enrolled
Ludwig Institute for Cancer Research
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of giving radiolabeled monoclonal antibody therapy directly into the abdominal cavity in treating patients who have advanced ovarian epithelial cancer.
Timeline
- Start
- 2003-11
- Primary completion
- 2005-05
- Completion
- 2006-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 111In-hu3S193 | Unknown | 185 mbq | Other |
| Subject | 90Y-hu3S193 | Unknown | 10 mg | Other |
| Subject | 90Y-hu3S193 | Unknown | 370 mbq | Other |
| Subject | 90Y-hu3S193 | Unknown | 555 mbq | Other |